Article
Immunology
Ivan Fan-Ngai Hung, Desmond Yat-Hin Yap, Terence Pok-Siu Yip, Ricky Ruiqi Zhang, Kelvin Kai-Wang To, Kwok-Hung Chan, Sydney Chi-Wai Tang, Sing-Leung Lui, Yotam Levin, Efrat Kochba, Johnson Yiu-Nam Lau, Man-Fung Yuen, Tak-Mao Chan, Kwok-Yung Yuen
Summary: Pretreatment with topical imiquimod before intradermal hepatitis B virus vaccination can improve seroprotection in dialysis patients, with high safety and favorable outcomes.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Joshua Y. Kwon, Nader D. Daoud, Jana G. Hashash, Michael F. Picco, Francis A. Farraye
Summary: Heplisav-B, a 2-dose vaccine, is an effective vaccine for HBV in patients with IBD, with an overall efficacy of 78.3%. Patients on an immunomodulator and/or 2 or more immunosuppressants had decreased response rate to vaccination.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Hematology
Maggie Han, Xiaoling Ye, Sharon Rao, Schantel Williams, Stephan Thijssen, Jeffrey Hymes, Franklin W. Maddux, Peter Kotanko
Summary: In hemodialysis patients, early initiation of dialysis in the morning is associated with a higher likelihood of seroconversion in response to hepatitis B vaccination.
BLOOD PURIFICATION
(2021)
Review
Immunology
Joan Ericka Flores, Alexander J. Thompson, Marno Ryan, Jessica Howell
Summary: Hepatitis B vaccination remains crucial for preventing liver cancer and achieving global hepatitis B elimination targets, but there is variability in vaccination coverage and challenges in meeting the targets.
Article
Immunology
Miia Virta, Anu Soininen, Dhaval M. Patel, Celine Petit, Cynthia Tabar, Olga Lyabis
Summary: The study showed that children who received hepatitis B vaccine at six years old maintained a good level of antibodies after vaccination, and demonstrated a strong immune response after hepatitis B challenge.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Chen-Hsuan Wu, Wei-Cheng Huang, Chien-Hung Chen, Sheng-Nan Lu
Summary: There is a high HBV infection rate and HBsAg carrier rate among high-risk Taiwanese children even after receiving HBIG and HB vaccinations. Cesarean section may protect newborns from becoming HBsAg carriers.
BIOMEDICAL JOURNAL
(2022)
Article
Immunology
Eric W. Hall, Mark K. Weng, Aaron M. Harris, Sarah Schillie, Noele P. Nelson, Ismael R. Ortega-Sanchez, Elizabeth Rosenthal, Patrick S. Sullivan, Ben Lopman, Jeb Jones, Heather Bradley, Eli S. Rosenberg
Summary: This study evaluated the economic benefits of universal hepatitis B vaccination among adults in the United States. The results showed that universal vaccination could significantly reduce the incidence of acute hepatitis B infections and improve health outcomes, but at an additional cost.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Review
Immunology
Tamsin Cargill, Eleanor Barnes
Summary: Chronic hepatitis B infection is a serious global health threat, and new treatments are urgently needed. Therapeutic vaccination aims to induce or boost existing HBV-specific immune responses to control HBV infection, but strategies to improve vaccine efficacy are still under exploration.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Takeshi Yoda, Hironobu Katsuyama
Summary: This study analyzed the hepatitis B antibody testing and vaccination records of 1064 first-year students from a medical school, and found that factors such as sex, body mass index, and vaccine type were significantly associated with antibody-negative individuals. Changes in vaccine types influenced the proportion of antibody-refractory cases, with no age association observed. Future analyses will continue to explore vaccine refractoriness while considering other variables.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Immunology
Percy A. Knolle, Li-Rung Huang, Anna Kosinska, Dirk Wohlleber, Ulrike Protzer
Summary: Chronic hepatitis B affects over 250 million individuals worldwide, with prophylactic vaccination only establishing protective immunity but not eliminating HBV infections in patients. Current research focuses on therapeutic vaccination strategies and additional immune stimulation measures to improve efficacy in treating chronic hepatitis B.
Article
Urology & Nephrology
Claudius Speer, Daniel Goeth, Louise Benning, Mirabel Buylaert, Matthias Schaier, Julia Grenz, Christian Nusshag, Florian Kaelble, Martin Kreysing, Paula Reichel, Maximilian Toellner, Asa Hidmark, Gerald Ponath, Paul Schnitzler, Martin Zeier, Caner Suesal, Christian Morath, Katrin Klein
Summary: Patients receiving long-term hemodialysis show a reduced antibody response to the first and second doses of the mRNA vaccine BNT162b2. The majority (82%) develop neutralizing antibodies after the second dose but at lower levels than healthy controls.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Review
Immunology
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Ferdousi Begum, Shaikh A. Shahed Hossain, Sukumar Sarker, Ananta Shrestha, Md Sakirul Islam Khan, Osamu Yoshida, Yoichi Hiasa
Summary: The article discusses strengthening and expanding the Hepatitis B vaccination program in SEARO countries with an emphasis on HepB and HepB-BD programs.
Article
Immunology
Md. Golam Dostogir Harun, Shariful Amin Sumon, Tahrima Mohsin Mohona, Aninda Rahman, Syed Abul Hassan Md Abdullah, Md. Saiful Islam, Md. Mahabub Ul Anwar
Summary: This study investigated the hepatitis B vaccination coverage among Bangladeshi healthcare workers in selected tertiary care hospitals. The overall vaccination coverage was found to be 66.6%, with the lowest coverage among cleaning staff. It was also found that many healthcare workers lacked training on hepatitis B virus prevention and management.
Article
Biotechnology & Applied Microbiology
Pu Shan, Zhibiao Wang, Jilai Li, Duoqian Wei, Zhuan Zhang, Shaojie Hao, Yibo Hou, Yunyang Wang, Shuxiang Li, Xudong Wang, Jing Xu
Summary: In this study, a new nano adjuvant PF3 was designed and prepared through microfluidization, combining saponin (Ginsenoside Rg1) and oil-in-water nano emulsion (NE). Compared to aluminum adjuvant, PF3 showed stronger humoral and cellular immune induction effects, as well as better immune enhancement and acceptable biosafety. Moreover, PF3 demonstrated high stability in vitro after 12 weeks storage at 4 and 37 degrees C. This study provided an adjuvant platform to replace traditional aluminum adjuvant in the design of recombinant vaccines.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Ruijun Wang, Chang Liu, Taoyang Chen, Yuting Wang, Chunsun Fan, Lingling Lu, Fengmin Lu, Chunfeng Qu
Summary: Among elder children/young adults who received hepatitis B virus (HBV) vaccination during infancy, the serological status of HBsAg(-)/anti-HBc(+) was frequently reported, indicating potential occult HBV infection (OBI). Neonatal HBV vaccination provided effective protection against OBI in mature adults, with unvaccinated individuals having a higher infection rate. The prevalence of HBsAg(-)/anti-HBc(+) increased with age in unvaccinated individuals.
HEPATOLOGY INTERNATIONAL
(2021)